Sarepta Therapeutics, Inc.

https://sarepta.com

Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of precision genetic medicines for rare diseases, with a primary focus on neuromuscular disorders. Headquartered in Cambridge, Massachusetts, the company's mission is to engineer advanced genetic medicines to rescue lives impacted by rare diseases, striving to accelerate the translation of genetic understanding into tangible treatments.

Sarepta's product portfolio includes RNA-targeted exon-skipping therapies such as EXONDYS 51, VYONDYS 53, and AMONDYS 45, alongside its gene therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl). These therapies are primarily aimed at treating Duchenne muscular dystrophy (DMD) and other neuromuscular conditions. The company also provides patient support services through programs like SareptAssist and SareptAlly.

As a leader in precision genetic medicine for rare neuromuscular disorders, Sarepta Therapeutics has seen significant developments, including the FDA's accelerated approval of ELEVIDYS in June 2023 and its subsequent label expansion in June 2024 for Duchenne muscular dystrophy. Douglas S. Ingram serves as the CEO and President. The company continues to advance its pipeline and reported substantial net product revenues, with Q1 2025 net product revenues reaching $611.5 million and full-year 2024 total net product revenue at $1.79 billion.

Latest updates

Sarepta siRNA Data Shows Early Promise in FSHD1, DM1 Trials

Event summary

  • Sarepta released initial Phase 1/2 clinical data for SRP-1001 (FSHD1) and SRP-1003 (DM1) siRNA therapies.
  • Early results indicate dose-dependent muscle exposure and biomarker effects with favorable tolerability.
  • Both SRP-1001 and SRP-1003 demonstrated knockdown of target protein/mRNA after a single dose.
  • The studies are combined Phase 1/2, single ascending dose (SAD)/multiple ascending dose (MAD), randomized, placebo-controlled trials.
  • Sarepta licenses its siRNA platform from Arrowhead Pharmaceuticals.

The big picture

Sarepta's siRNA platform represents a significant bet on RNA-targeted therapies for rare neuromuscular diseases, addressing a long-standing challenge of drug delivery and safety. The early data validates the company's approach but the market for rare disease treatments is highly competitive, and success hinges on demonstrating clinical efficacy and navigating regulatory hurdles. Arrowhead's licensing agreement provides Sarepta access to a key technology, but also introduces a dependency on a third party for platform development.

What we're watching

Efficacy Validation
Whether the observed biomarker effects translate into meaningful clinical efficacy in later-stage trials remains to be seen, given the historically challenging nature of FSHD1 and DM1 treatments.
Delivery Scale
The αvβ6 integrin-targeted delivery platform's ability to maintain robust siRNA muscle delivery at higher doses will be critical for achieving therapeutic impact.
Competitive Landscape
The success of Sarepta’s siRNA platform will be weighed against other emerging gene therapies and RNA-targeted approaches for FSHD1 and DM1, potentially impacting market share and pricing.

Sarepta to Present Early Data on siRNA Pipeline for Muscular Dystrophies

Event summary

  • Sarepta Therapeutics will present Phase 1/2 clinical data for SRP-1001 (FSHD1) and SRP-1003 (DM1) on March 25, 2026.
  • The data represents early results from ascending dose studies.
  • The webcast and conference call will begin at 8:30 am Eastern Time.
  • SRP-1001 targets facioscapulohumeral muscular dystrophy type 1 (FSHD1).
  • SRP-1003 targets myotonic dystrophy type 1 (DM1).

The big picture

Sarepta's foray into siRNA therapies for muscular dystrophies marks a strategic diversification beyond its existing gene therapy portfolio. The success of SRP-1001 and SRP-1003 will be crucial for validating Sarepta’s broader platform and expanding its addressable market within the rare disease space, which is attracting significant investment and competition. Early data will be a key indicator of the viability of this new therapeutic modality for these debilitating conditions.

What we're watching

Clinical Efficacy
The initial data will be scrutinized for signs of efficacy and safety, as siRNA therapies for muscular dystrophies represent a relatively new therapeutic approach.
Dose Response
The observed dose-response relationship will be critical in determining the optimal therapeutic window and guiding future development plans for both SRP-1001 and SRP-1003.
Competitive Landscape
The results will be compared against emerging therapies from other companies targeting FSHD1 and DM1, potentially impacting Sarepta’s market positioning and future pipeline strategy.

Sarepta Seeks Traditional FDA Approval for DMD Therapies Amid Conflicting Trial Data

Event summary

  • Sarepta has requested a meeting with the FDA to submit supplemental new drug applications (sNDAs) for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approval.
  • The request is based on data from the ESSENCE confirmatory study, real-world evidence, and favorable safety profiles.
  • The ESSENCE study's topline results showed a statistically insignificant 0.06 steps/second difference in the primary endpoint (P=0.309).
  • An updated ESSENCE analysis excluding data from 23 participants during the COVID-19 pandemic showed a statistically significant difference of 0.12 steps/second (P=0.050).
  • Sarepta intends to submit the sNDAs by the end of April 2026.

The big picture

Sarepta's pursuit of traditional approval highlights the ongoing challenge of demonstrating long-term efficacy in rare disease treatments, particularly when relying on real-world data. The ESSENCE trial’s mixed results underscore the complexities of conducting clinical trials in vulnerable patient populations and the potential for data revisions to significantly alter trial outcomes. The company's PMO portfolio, treating over 1,800 patients, represents a significant foothold in the DMD market, but continued success hinges on navigating regulatory hurdles and demonstrating sustained clinical value.

What we're watching

Regulatory Headwinds
The FDA’s assessment of the ESSENCE data and real-world evidence will be critical; a rejection or significant pushback could impact Sarepta’s valuation and future development plans.
Clinical Efficacy
How the company frames the conflicting ESSENCE data—the initial non-significant result versus the revised analysis—will influence investor perception of the therapies’ true clinical benefit.
Commercial Impact
Whether a conversion to traditional approval will materially impact payer coverage and patient access, and ultimately, Sarepta’s revenue trajectory, remains to be seen.

Sarepta Initiates Trial to Mitigate ELEVIDYS Liver Injury Risk

Event summary

  • Sarepta has begun screening and enrollment for ENDEAVOR Cohort 8, a Phase 1b study evaluating ELEVIDYS gene therapy.
  • The cohort will assess prophylactic sirolimus treatment to reduce acute liver injury (ALI) risk in non-ambulatory Duchenne patients.
  • Approximately 25 U.S. participants are being enrolled, receiving 14 days of peri-infusion sirolimus followed by 12 weeks of continued dosing.
  • The trial will measure incidence of ALI and dystrophin expression at 12 weeks as primary endpoints.

The big picture

Sarepta's ongoing efforts to refine ELEVIDYS’ safety profile are crucial given the therapy's boxed warning for acute liver injury. This cohort represents a targeted attempt to expand the eligible patient population – non-ambulatory individuals – who have been largely excluded due to heightened risk. The trial's outcome will significantly influence investor confidence and the company's ability to capitalize on the growing gene therapy market for Duchenne muscular dystrophy.

What we're watching

Safety Profile
The success of this cohort hinges on whether sirolimus effectively reduces ALI without compromising ELEVIDYS efficacy or introducing new safety concerns, which will be critical for broader adoption.
Regulatory Approval
The FDA's acceptance of this enhanced safety protocol as a pathway to broader ELEVIDYS use in non-ambulatory patients will dictate the therapy's long-term commercial viability.
Patient Adoption
The willingness of physicians and patients to adopt a more complex treatment regimen involving sirolimus will be a key factor in ELEVIDYS’s uptake, especially given existing safety concerns.

Sarepta's Scholarship Program Signals Ongoing Community Investment

Event summary

  • Sarepta Therapeutics has opened applications for the 9th annual Route 79 Duchenne Scholarship Program, offering up to $5,000 scholarships.
  • The program will award scholarships to approximately 25 individuals: 20 living with Duchenne muscular dystrophy and 5 siblings.
  • Applications are accepted until May 15, 2026, with recipients notified by July 31, 2026.
  • The scholarship program is managed by an independent committee, blinded to recipients' treatment status with Sarepta products.

The big picture

Sarepta's Route 79 scholarship program represents a sustained effort to build goodwill and maintain a strong relationship with the Duchenne muscular dystrophy community. While the $5,000 scholarship amount is relatively modest, the nine-year commitment and consistent structure demonstrate a long-term investment in patient and family support, which can be a valuable asset in a field heavily reliant on patient advocacy and access.

What we're watching

Program Scale
The consistency of the program's size (25 scholarships annually) suggests a deliberate, budgeted commitment, but future expansion could signal increased financial flexibility or a shift in strategic priorities.
Patient Engagement
How Sarepta leverages the program's recipients and their families for broader patient advocacy and disease awareness initiatives will be a key indicator of its long-term community engagement strategy.
Treatment Impact
The program's continued existence, despite advancements in Duchenne treatment, indicates that Sarepta views community support as a vital element of its brand and patient relations, regardless of therapeutic progress.

Sarepta to Present Long-Term Data on Gene Therapy, Exon-Skipping Treatments

Event summary

  • Sarepta Therapeutics will present data at the Muscular Dystrophy Association (MDA) Clinical & Scientific Congress, March 8-11, 2026.
  • Key presentations include a late-breaking oral presentation on delandistrogene moxeparvovec (gene therapy) with up to three years of follow-up data.
  • Data will also be presented on golodirsen and casimersen (exon-skipping treatments) and a real-world analysis of survival in patients treated with Sarepta’s medicines.
  • A pooled safety analysis of delandistrogene moxeparvovec clinical trials will cover up to 7.5 years of patient follow-up.

The big picture

Sarepta’s continued focus on long-term data generation underscores the increasing importance of demonstrating durable efficacy and safety in rare disease gene therapies. The company’s leadership position in this niche market, valued at approximately $3.5 billion, is predicated on maintaining a robust pipeline and generating compelling clinical evidence. The presentation at MDA represents a key opportunity to reinforce Sarepta’s position and address investor concerns regarding the long-term value proposition of its treatments.

What we're watching

Clinical Validation
The long-term safety and efficacy data on delandistrogene moxeparvovec will be critical in solidifying its commercial viability and justifying its premium pricing, especially given the scrutiny of gene therapy cost-effectiveness.
Real-World Evidence
The real-world survival analysis will provide a more nuanced view of treatment impact beyond controlled clinical trials, potentially influencing payer coverage decisions and patient access.
Regulatory Risk
The FDA’s assessment of the pooled safety data, particularly regarding adverse events within the first 60 days post-infusion, could impact future approval pathways for Sarepta’s gene therapy programs.

Sarepta's 2025 Results Show Resilience Amidst ELEVIDYS Labeling Shift

Event summary

  • Sarepta reported $442.9 million in revenue for Q4 2025, down from $658.4 million in Q4 2024, primarily due to changes in ELEVIDYS labeling.
  • The company ended 2025 with $953.8 million in cash, a decrease from $1.5 billion at the end of 2024.
  • Sarepta refinanced $291.4 million of its 2027 convertible notes, pushing the maturity to 2030 and reducing near-term debt overhang.
  • Positive three-year data from the EMBARK study showed continued motor function preservation in ELEVIDYS-treated patients.

The big picture

Sarepta's 2025 performance reflects the challenges of navigating regulatory changes and market access hurdles for gene therapies. While the company maintains a strong cash position and a durable franchise with ELEVIDYS, its future success hinges on expanding its product portfolio and demonstrating the long-term clinical and commercial viability of its pipeline. The company's ability to execute on its clinical development programs and manage regulatory risk will be crucial for sustaining its position in the competitive gene therapy landscape.

What we're watching

Labeling Risk
The company's ability to regain market share for ELEVIDYS following the updated prescribing information and potential pathway back to non-ambulatory patients will be a key indicator of future revenue growth.
Clinical Execution
The success of the ENDEAVOR Cohort 8 trial evaluating enhanced immunosuppression regimens will be critical for expanding ELEVIDYS access and mitigating safety concerns.
Pipeline Progress
The advancement of Sarepta’s siRNA pipeline, particularly SRP-1005 for Huntington’s disease, will determine the company’s long-term growth trajectory beyond its current Duchenne franchise.

Sarepta Gains New Zealand Approval for Huntington's Trial

Event summary

  • Sarepta Therapeutics received approval from New Zealand’s Medsafe for a clinical trial application (CTA) for Study SRP-1005-101 (INSIGHTT).
  • The Phase 1 trial will evaluate the safety and tolerability of SRP-1005, an siRNA therapeutic for Huntington’s Disease, in approximately 24 participants.
  • The trial is expected to begin in the second quarter of 2026.
  • SRP-1005 utilizes a TfR1-targeted delivery approach to efficiently penetrate the blood-brain barrier.

The big picture

Huntington’s Disease represents a significant unmet medical need, with limited treatment options available. Sarepta’s entry into this space with an siRNA-based therapy positions them to potentially capture a substantial portion of a market estimated to include 40,000 symptomatic patients and 200,000 at-risk individuals. The success of SRP-1005 will hinge on its ability to demonstrate both safety and efficacy, and will be a key test of Sarepta’s broader siRNA platform strategy.

What we're watching

Clinical Efficacy
The initial Phase 1 data will be critical in assessing whether SRP-1005’s targeted delivery system effectively achieves the intended protein knockdown in human subjects, a key determinant of potential therapeutic benefit.
Regulatory Pathway
The acceptance of the CTA by Medsafe, while positive, doesn't guarantee broader regulatory approval; future interactions with other agencies will reveal the overall development pathway.
Competitive Landscape
The progress of SRP-1005 will be weighed against other emerging Huntington’s disease therapies, as the field rapidly develops and patient expectations increase.

Sarepta to Release 3-Year ELEVIDYS Data, Key Test for Gene Therapy Validation

Event summary

  • Sarepta Therapeutics will release 3-year topline functional results from the EMBARK Phase 3 study on January 26, 2026.
  • The EMBARK study (Study 9001-301) evaluates ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory Duchenne muscular dystrophy patients aged 4-7.
  • The study is global, randomized, and placebo-controlled.
  • The presentation will be webcast and available via conference call, registration required.

The big picture

The EMBARK study represents a pivotal moment for gene therapy in Duchenne muscular dystrophy, a market with significant unmet need. Success here could validate the gene therapy approach and pave the way for broader adoption, while failure could significantly dampen enthusiasm and investment in the field. The results will be closely watched by competitors developing similar therapies and by payers evaluating the cost-effectiveness of these novel treatments.

What we're watching

Efficacy Durability
The 3-year data will be critical in assessing the long-term functional benefits of ELEVIDYS, and whether initial improvements are sustained, which will heavily influence future adoption and reimbursement.
Regulatory Scrutiny
Given the ongoing debate around gene therapy efficacy and pricing, the data’s reception by regulatory bodies will shape future approval pathways and market access for Sarepta’s product and competitors’ offerings.
Commercial Impact
The EMBARK results will directly influence investor sentiment and potentially impact Sarepta's valuation, especially considering the high expectations surrounding ELEVIDYS’s commercial potential within the Duchenne muscular dystrophy market.

Sarepta Posts $1.86B in 2025 Revenue, ELEVIDYS Sales Impacted by Flu Season

Event summary

  • Sarepta Therapeutics reported preliminary net product revenues of $369.6 million for Q4 2025 and $1.86 billion for full-year 2025.
  • ELEVIDYS generated $110.4 million in Q4 2025 revenue and $898.7 million for the full year, impacted by rescheduling of patient infusions.
  • The PMO franchise contributed $259.2 million in Q4 2025 and $965.6 million for the full year.
  • As of December 31, 2025, Sarepta held approximately $953.8 million in cash, cash equivalents, restricted cash, and investments.

The big picture

Sarepta's strong revenue performance underscores the growing market for precision genetic medicine targeting rare diseases. The company's reliance on ELEVIDYS, while generating significant revenue, also exposes it to regulatory and safety risks that could impact future growth. The company's cash position provides flexibility to invest in its pipeline, but continued success will depend on navigating these challenges and demonstrating the value of its therapies.

What we're watching

Sales Execution
Sarepta's ability to exceed its $500 million annual sales floor for ELEVIDYS will hinge on the success of planned initiatives, and the company’s lack of detailed guidance suggests uncertainty around their impact.
Regulatory Risk
The FDA’s ongoing scrutiny of gene therapies, particularly regarding liver safety concerns associated with ELEVIDYS, could lead to further restrictions or labeling changes impacting adoption.
Pipeline Progress
The advancement of Sarepta’s siRNA pipeline will be critical for long-term growth, and the company’s financial strength will determine the pace and scope of its development efforts.

Sarepta Advances Huntington's Therapy into Human Trials

Event summary

  • Sarepta Therapeutics submitted a Clinical Trial Application (CTA) for SRP-1005 (formerly ARO-HTT) to Medsafe in New Zealand.
  • The INSIGHTT Phase 1 trial, expected to begin in Q2 2026, will enroll approximately 24 participants.
  • SRP-1005 is an siRNA therapy designed to target and reduce the huntingtin protein, a key driver of Huntington’s Disease.
  • Preclinical data suggest SRP-1005 can achieve significant protein knockdown in deep brain regions.

The big picture

Sarepta’s entry into the Huntington’s Disease therapeutic space represents a significant expansion of its pipeline beyond rare muscular dystrophies. Huntington’s Disease, affecting an estimated 40,000 people in the U.S. alone, presents a substantial unmet medical need and a potential multi-billion dollar market if Sarepta can demonstrate efficacy with SRP-1005. The company’s reliance on siRNA technology, while promising, also carries inherent risks related to delivery and potential off-target effects.

What we're watching

Regulatory Approval
The speed of Medsafe's approval will dictate the timeline for initiating the INSIGHTT trial and subsequent development milestones, potentially impacting investor sentiment.
Clinical Efficacy
Early data from the Phase 1 trial will be critical in assessing the therapeutic potential of SRP-1005, as Huntington's disease has historically seen limited treatment options.
Delivery Efficiency
The success of Sarepta’s TfR1 delivery approach in achieving consistent and robust blood-brain barrier penetration will be a key determinant of the therapy's overall effectiveness.

Sarepta Management to Address J.P. Morgan Healthcare Conference

Event summary

  • Sarepta Therapeutics executives will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
  • The presentation will be webcast live and archived for 90 days.
  • A Q&A session will follow the presentation.
  • The conference takes place in San Francisco, California.

The big picture

Presentations at the J.P. Morgan Healthcare Conference are a key event for biotech companies seeking to engage with investors and analysts. Sarepta's participation underscores its continued focus on rare disease genetic medicine, a sector attracting significant investment. The conference provides a platform to shape narratives and influence valuation, particularly as the company navigates the complexities of clinical development and commercialization.

What we're watching

Pipeline Progress
The presentation's focus on Sarepta's pipeline beyond Duchenne muscular dystrophy will indicate the company's diversification strategy and potential for future revenue streams, which is critical given the maturity of existing therapies.
Financial Outlook
Management’s commentary on R&D spending and commercialization costs will reveal the sustainability of Sarepta’s current growth trajectory and its ability to fund future development programs.
Investor Sentiment
The tone and content of the Q&A session will provide insight into investor concerns and expectations regarding Sarepta’s long-term prospects and competitive positioning.
CID: 286